Clinical Efficacy Evaluation of Buxue Yimu Pill in Promoting Post-Abortion Recovery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2026001323

Enrollment

Unknown

Registered

2026-05-26

Start date

2026-05-25

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Induced abortion

Interventions

Experimental Group:Buxue Yimu Pill + Standard Treatment Group

Control Group:None

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Confirmed intrauterine pregnancy (5-10 weeks gestation) requiring induced abortion; (2) Age 18-45 years with good health and regular menstrual cycles (21-35 days); (3) No contraindications for vacuum aspiration surgery, normal vaginal discharge and blood tests, absence of vaginitis or acute pelvic inflammatory disease; (4) Meeting TCM diagnostic criteria for Qi-Blood deficiency syndrome; (5) Voluntary participation with signed informed consent and completed follow-up.

Exclusion criteria

Exclusion criteria: (1) Comorbid organic diseases of heart, brain, liver, kidney, hematopoietic system, or mental disorders; (2) History of endocrine disorders, uterine organic lesions, reproductive system tumors, or congenital malformations; (3) Intrauterine procedures within past 3 months; (4) Comorbid adenomyosis or endometritis; (5) Allergic constitution or known hypersensitivity to trial drugs; (6) Recent use (within 1 month) of hormonal medications; (7) Recent use (within 1 month) of TCM formulas containing main components of Buxue Yimu Pill; (8) Intraoperative/postoperative complications including severe hemorrhage, uterine perforation, incomplete abortion, or retained products.

Design outcomes

Primary

Measure	Time frame
Endometrial thickness;Endometrial volume;Endometrial vascularization index;Subendometrial blood flow index;Subendometrial vascular blood flow index;Subendometrial resistance index;Endometrial blood flow fluctuation index;	—

Secondary

Measure	Time frame
Days of post-abdominal pain after induced abortion;Days of vaginal bleeding;Menstrual resumption time;Menstrual flow score;Abnormal uterine bleeding incidence;Serum human vascular endothelial growth factor;Human transforming growth factor;Human laminin;Human fibronectin;Interleukin-18;Interleukin-10;Whole blood viscosity;Plasma viscosity;TCM syndrome score;Abdominal distension, nausea, breast tenderness;SF-36 Quality of Life Score;	—

Measure

Time frame

Days of post-abdominal pain after induced abortion;Days of vaginal bleeding;Menstrual resumption time;Menstrual flow score;Abnormal uterine bleeding incidence;Serum human vascular endothelial growth factor;Human transforming growth factor;Human laminin;Human fibronectin;Interleukin-18;Interleukin-10;Whole blood viscosity;Plasma viscosity;TCM syndrome score;Abdominal distension, nausea, breast tenderness;SF-36 Quality of Life Score;

—

Countries

China

Contacts

Public ContactZhang Guohui

Fujian Province Zhangzhou City Hospital

929487831@qq.com13358332023

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026